Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer

Cancer

Volumn 118, Issue 4, 2012, Pages 960-972

  Su, Yun ^a,b   Loos, Martin ^c   Giese, Natalia ^a   Metzen, Eric ^d   Büchler, Markus W ^a   Friess, Helmut ^c   Kornberg, Arno ^c   Büchler, Peter ^c,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SOUTHEAST UNIVERSITY   (China)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Klinikum Kempten   (Germany)

Author keywords

angiogenesis; hypoxia; hypoxia inducible factor; pancreatic cancer; prolyl hydroxylase 2

Indexed keywords

CYCLIN D1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE 2; PROTEIN P21; UNCLASSIFIED DRUG; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL METABOLISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROLYL HYDROXYLASE 2 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ANGIOGENESIS; CARCINOGENESIS; DNA TRANSFECTION; DOWN REGULATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; MAJOR CLINICAL STUDY; PHD2 GENE; TUMOR INVASION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANOXIA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROCOLLAGEN-PROLINE DIOXYGENASE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HETEROLOGOUS; YOUNG ADULT;

EID: 84856778101     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26344     Document Type: Article

References (31)

1. Semenza GL,. Life with oxygen. Science. 2007; 318: 62-64.
2. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell. 2000; 100: 57-70.
3. Buchler P, Reber HA, Lavey RS, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res. 2004; 120: 295-303.
4. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003; 26: 56-64.
5. Marxsen JH, Stengel P, Doege K, et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J. 2004; 381: 761-767.
6. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468-472.
7. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107: 43-54.
8. Bruick RK, McKnight SL,. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294: 1337-1340.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271-275.
10. Berra E, Ginouves A, Pouyssegur J,. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 2006; 7: 41-45.
11. Pouyssegur J, Dayan F, Mazure NM,. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006; 441: 437-443.
12. Ryan HE, Lo J, Johnson RS,. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17: 3005-3015.
13. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM,. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000; 6: 1335-1340.
14. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394: 485-490.
15. Acker T, Diez-Juan A, Aragones J, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell. 2005; 8: 131-141.
16. Lee KA, Lynd JD, O'Reilly S, Kiupel M, McCormick JJ, LaPres JJ,. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res. 2008; 6: 829-842.
17. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006; 103: 654-659.
18. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008; 359: 2685-2692.
19. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ,. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009; 15: 527-538.
20. Mazzone M, Dettori D, Leite DO, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136: 839-851.
21. Buchler P, Reber HA, Tomlinson JS, et al. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia. 2009; 11: 196-206.
22. Reyes H, Reisz-Porszasz S, Hankinson O,. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992; 256: 1193-1195.
23. Buchler P, Gazdhar A, Schubert M, et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005; 242: 791-800.
24. Buchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ,. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia. 2007; 9: 119-127.
25. El Fitori J, Su Y, Buchler P, et al. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer. 2007; 110: 1457-1468.
26. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002; 38: 1564-1579.
27. von MZ, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000; 119: 1358-1372.
28. Wen W, Ding J, Sun W, et al. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res. 2010; 70: 2010-2019.
29. Zhang Q, Gu J, Li L, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009; 16: 413-424.
30. Salnikow K, Costa M, Figg WD, Blagosklonny MV,. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 2000; 60: 5630-5634.
31. Schultz K, Murthy V, Tatro JB, Beasley D,. Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1α-dependent mechanisms. Am J Physiol Lung Cell Mol Physiol. 2009; 296: L921-L927.